“Catalyst continues to prove its capabilities as a leader in oncology clinical development and as a preferred strategic acquirer for growing businesses,” said Vern Davenport, Partner at NovaQuest Capital Management and Catalyst Board Chairman. “Our complementary service offerings and therapeutic area alignment will improve outcomes for all our clients.” “We are thrilled to be working with Aptus Clinical to expand our reach in the European market, serving clients around the globe to help develop innovative new therapies, improve patient outcomes and enhance our company’s long-term impact,” said Catalyst Clinical Research CEO, Nick Dyer. Positioned at the forefront of novel cancer treatment trends, Catalyst’s active portfolio serves more than 5,300 cancer patients in need and will grow by nearly 600 patients concurrent to this acquisition.
Aptus healthcare trial#
and Europe.Ĭatalyst’s offerings will now encompass extensive and expanded clinical consulting services, as it inherits Aptus’ strong and established relationship with the Experimental Cancer Medicine Centre (ECMC) network to support trial set-up and clinical design input. Together, the two entities will become one multi-region clinical research organization with an accelerated growth trajectory in both the U.S.
WILMINGTON, N.C. and ALDERLEY PARK, England, May 4, 2022 /PRNewswire/ - Today, Catalyst Clinical Research, a market-leading provider of clinical research services, announced a strategic acquisition of Aptus Clinical to expand the geographic reach of the two companies, and to enhance patient access to advanced, life-changing therapies. The transaction capitalizes on the two company’s combined geographic strengths, complementary service offerings and therapeutic expertise to advance industry-leading research for improved patient outcomes.
0 kommentar(er)
